KALV News and Press, KalVista Pharmaceuticals Inc. From 05/01/24

- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive results and set path to positive cash flow – KalVist...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, ef...

2024-04-12 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the 23 rd Annual Needham Virtu...

2024-03-23 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical co...

2024-03-13 18:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercial...

2024-03-11 06:37:30 ET More on KalVista Pharmaceuticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies ...

2024-03-11 06:37:30 ET More on KalVista Pharmaceticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies D...